India Eases Medical Device Rules for Outsourced Sterilisation, Adds EU to Recognised Regulatory Jurisdictions

India has proposed changes to its medical device regulations that could make it easier for manufacturers to outsource sterilisation and bring certain devices to the Indian market more quickly. The Union Health Ministry has proposed amendments to the Medical Devices Rules, 2017, including removal of the requirement for a separate licence when sterilisation is outsourced to an already licensed facility.

The proposed changes also expand the list of countries and regulatory jurisdictions whose approvals can be considered for waiving clinical investigation requirements in India. The European Union has been added to this list, alongside jurisdictions already recognised under the regulatory framework.

The amendments are aimed at improving ease of doing business without removing regulatory controls. For medical device companies, the changes could reduce administrative duplication, lower compliance friction and make manufacturing arrangements more flexible. For patients and healthcare providers, however, the important question will be whether faster market access continues to be accompanied by adequate evidence of safety, quality and performance.

What Has the Government Proposed?

The Union Health Ministry has proposed amendments to the Medical Devices Rules, 2017 with three broad objectives: simplifying regulatory procedures, making testing requirements more predictable and facilitating faster access to eligible medical devices.

The changes include a proposed amendment to Rule 44, which deals with sterilisation arrangements.

Under the proposed change, a manufacturer that sends its medical devices to an external sterilisation facility holding a valid licence under the Medical Devices Rules, 2017, would no longer need to obtain a separate loan licence specifically for that sterilisation activity.

The proposal is intended to remove an additional regulatory step where the sterilisation facility is already operating under the medical device regulatory framework.

Why Is Outsourced Sterilisation Important?

Sterilisation is not an optional finishing step for many medical devices. It is a critical part of manufacturing for products that must be free from viable microorganisms before they are used on or inside patients.

Medical device companies may not always operate their own sterilisation plants. Instead, they can use specialised facilities with the equipment, processes and technical expertise required to sterilise particular products.

Outsourcing can therefore make commercial and operational sense, especially for manufacturers that do not have sufficient production volumes to justify building and maintaining dedicated sterilisation infrastructure.

But sterilisation is also a high-stakes process.

If it is inadequate, microbial contamination can pose risks to patients. If it is excessively harsh or poorly controlled, it can potentially affect the material, packaging or performance characteristics of a device.

This is why the regulatory framework needs to achieve two things at once: allow manufacturers to use specialised facilities efficiently while ensuring that the sterilisation process remains properly controlled.

What Changes Under the Proposed Rule 44 Amendment?

The proposed amendment is essentially aimed at removing duplication.

When a manufacturer outsources sterilisation to a facility that already holds a valid licence under the Medical Devices Rules, the manufacturer would no longer need to obtain a separate loan licence for that sterilisation activity.

This does not mean that outsourced sterilisation would become unregulated.

The sterilisation facility would still need to operate within the applicable regulatory framework. The key change is that the manufacturer would not have to secure an additional licence merely because the sterilisation operation is being performed by another appropriately licensed facility.

The distinction is important because regulatory simplification is not the same as regulatory deregulation.

Why the Change Could Matter to Medical Device Manufacturers

Medical device manufacturing frequently involves specialised processes performed by different organisations.

A company may design a device, manufacture or assemble it at one location, use a separate facility for a particular process and then distribute the finished product through another part of its supply chain.

Every additional approval requirement can increase administrative work, documentation, processing time and compliance costs.

If an outsourced sterilisation facility is already licensed and subject to regulatory oversight, requiring the manufacturer to obtain another licence for the same activity can create an additional layer of paperwork without necessarily adding equivalent safety value.

The proposed amendment attempts to address that problem.

For smaller manufacturers in particular, reducing unnecessary administrative duplication could make it easier to use specialised third-party infrastructure rather than investing in expensive facilities of their own.

What Is a Loan Licence?

A loan licence is a regulatory mechanism through which an applicant can use the manufacturing facilities of another licensed entity for specified activities, subject to the applicable rules.

In the context of the proposed amendment, the government is seeking to avoid a situation in which a manufacturer needs a separate loan licence solely because it has outsourced sterilisation to an already licensed medical-device sterilisation facility.

The proposed approach recognises the regulatory status of the facility performing the specialised activity instead of requiring another parallel licensing process.

EU Added to Recognised Regulatory Jurisdictions

The second major element of the proposed changes concerns clinical investigation requirements.

The government has expanded the list of countries and regulatory jurisdictions whose approvals can support a waiver of clinical investigation requirements in India for eligible medical devices.

The European Union has now been added to the stringent regulatory jurisdictions recognised under the framework.

This is significant because regulatory approval in a well-established jurisdiction can provide evidence that a medical device has already undergone scrutiny under another robust regulatory system.

However, recognising such approvals does not necessarily mean that every device approved elsewhere will automatically enter India without regulatory review.

Eligibility, classification, documentation and other requirements under India’s own regulatory framework remain important.

Why Clinical Investigation Requirements Matter

Clinical investigation is designed to generate evidence about how a medical device performs in humans and whether its use presents unacceptable risks.

For some devices, particularly those involving significant interaction with the human body, clinical evidence can be an important part of determining safety and performance.

At the same time, requiring a company to repeat essentially equivalent investigations in every country can delay access to products that have already undergone extensive assessment elsewhere.

This creates a regulatory balancing act.

Authorities need enough evidence to protect patients while avoiding unnecessary duplication that adds time and cost without generating meaningful new information.

The proposed recognition of additional stringent regulatory jurisdictions attempts to move towards that balance.

What Does Adding the EU Actually Mean?

The European Union has a mature regulatory system for medical devices. Including the EU among recognised stringent regulatory jurisdictions could allow eligible devices that meet the relevant criteria to benefit from a waiver of clinical investigation requirements in India.

The practical effect could be particularly relevant to manufacturers that have already invested in obtaining regulatory clearance for the European market.

Instead of treating overseas regulatory evidence as having limited relevance, India’s framework can use it as part of its assessment for qualifying products.

This could reduce duplication and potentially shorten the route from international approval to Indian market entry.

Faster Market Access Does Not Mean Lower Safety Standards

This is one of the most important distinctions surrounding the proposed reforms.

A faster regulatory pathway does not automatically mean that a medical device is subject to no scrutiny.

Medical devices can vary enormously in complexity. A simple external product and a device that is implanted inside the body do not present identical safety questions.

Regulation therefore has to consider factors such as intended use, risk classification, materials, duration of contact with the body and potential consequences of device failure.

The government’s proposal is aimed at reducing unnecessary duplication for eligible devices rather than creating a blanket exemption from India’s regulatory requirements.

Why Testing Fees Are Also Being Standardised

The proposed amendments also seek to standardise testing fees.

Testing is an essential part of medical device regulation, but uncertainty around costs can create difficulties for manufacturers planning product development and regulatory submissions.

Standardised fees can make the system more predictable.

For a manufacturer, predictability matters almost as much as the absolute cost. Companies need to estimate regulatory expenses before deciding whether to introduce a product, expand manufacturing capacity or invest in additional testing.

A clearer fee structure can therefore reduce uncertainty and make regulatory planning easier.

How the Proposed Changes Could Affect the Medical Device Industry

Potential Benefits for Indian Patients

The immediate beneficiaries of regulatory reform may appear to be manufacturers, but the effects can eventually reach patients.

Medical device innovation depends partly on how efficiently new technologies can move from development to clinical use.

If unnecessary administrative steps delay the introduction of useful devices, patients may have to wait longer for access. A more predictable regulatory system could help reduce such delays.

Faster access can be particularly relevant for specialised technologies where domestic alternatives are limited.

At the same time, speed should not become the only measure of regulatory success. A device that reaches the market quickly but lacks adequate evidence of safety or performance would undermine the purpose of regulation.

The strongest regulatory system is therefore not necessarily the one that approves devices fastest. It is the one that removes avoidable delays while preserving meaningful safety checks.

Potential Benefits for Smaller Manufacturers

Large medical device companies may have the resources to maintain dedicated manufacturing, testing and sterilisation infrastructure.

Smaller companies may not.

For them, access to specialised third-party facilities can be critical.

The proposed sterilisation change could make this model easier to operate by reducing the need for additional licensing when the outsourced facility is already licensed under the Medical Devices Rules.

This could encourage a more flexible manufacturing ecosystem in which companies focus on their core capabilities while using specialised partners for processes that require significant capital investment.

India’s Larger Medical Device Ambition

The proposed amendments also fit into a broader effort to strengthen India’s medical device ecosystem.

India has traditionally relied significantly on imported medical devices across several categories. Building a stronger domestic industry requires not only manufacturing capacity but also regulatory systems that are efficient, predictable and internationally credible.

A modern regulatory framework can help attract investment by reducing uncertainty around approvals and compliance.

Recognising evidence from stringent overseas jurisdictions can also make India a more practical market for international manufacturers while creating opportunities for domestic companies seeking to develop globally competitive products.

The challenge will be ensuring that ease of doing business and patient safety develop together rather than being treated as competing goals.

What Manufacturers Should Watch Next

The announcement concerns proposed amendments, so manufacturers and other stakeholders will need to pay attention to the final notified rules and their implementation details.

Companies should particularly examine how the final provisions define eligibility, documentation, recognised regulatory approvals and the operational responsibilities of manufacturers and outsourced facilities.

The practical impact of a regulatory amendment often depends on these details.

A broad policy announcement can signal the direction of reform, but the actual compliance pathway is determined by the final legal text and subsequent regulatory implementation.

Regulatory Simplification vs Regulatory Dilution

The proposed reforms highlight a distinction that is increasingly important in healthcare regulation.

Regulatory simplification means removing unnecessary duplication while keeping meaningful safeguards.

Regulatory dilution would mean reducing the evidence or oversight needed to protect patients.

The two are not the same.

Removing a separate licence requirement for a sterilisation facility that already holds an appropriate licence can be viewed as eliminating duplication. Similarly, recognising credible regulatory evidence from a stringent jurisdiction can reduce repeated investigations without necessarily eliminating regulatory assessment.

The success of the reforms will ultimately depend on whether that balance is maintained during implementation.

What Could Change for India’s Medical Device Market?

If implemented effectively, the proposed amendments could produce a medical device regulatory system that is more predictable without becoming less rigorous.

Manufacturers could benefit from simpler outsourced sterilisation arrangements, clearer testing costs and potentially faster pathways for eligible devices with recognised international approvals.

Healthcare providers could benefit if those changes lead to greater availability of useful technologies.

Patients could ultimately benefit through earlier access to appropriately assessed devices.

But these outcomes are not automatic. They depend on effective implementation, competent regulatory oversight and continued attention to post-market safety.

Conclusion: A Shift Toward Smarter Medical Device Regulation

India’s proposed amendments to the Medical Devices Rules, 2017 represent a move towards reducing procedural barriers in the medical device sector.

The proposal to remove a separate loan licence requirement for manufacturers that outsource sterilisation to an already licensed facility could eliminate an important layer of administrative duplication. The addition of the European Union to recognised stringent regulatory jurisdictions could, for eligible products, help reduce repeated clinical investigation requirements and facilitate faster access to the Indian market.

Standardising testing fees could provide another practical benefit by making regulatory costs easier to anticipate.

The larger significance is that India appears to be moving towards a regulatory model that places greater emphasis on risk-based oversight, international regulatory convergence and predictable compliance.

The key test will be implementation. Faster approvals are valuable only when accompanied by reliable evidence, effective quality controls and strong post-market monitoring.

If the balance is maintained, the proposed reforms could make India’s medical device sector easier to navigate for manufacturers while preserving the safeguards that matter most to patients.